A new study from the Washington University (WashU) School of Medicine in St. Louis suggests that existing immunotherapy drugs already used to treat inflammatory conditions may offer a potential treatment for the millions of Americans living with heart failure, a condition now projected to affect one in four people during their lifetime.
Heart failure (HF) progressively weakens the heart’s ability to pump blood effectively. While it often develops after heart attacks or viral infections, the key culprit is scar tissue that forms in the heart muscle, interfering with normal contractions and degrading cardiac function. Current treatments can only slow the disease’s progression and manage symptoms —there is no cure.
